Oswaldo Cruz Foundation (Fiocruz)
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19 After 2 Years of the Pandemic
After 2 years of the COVID-19 pandemic, we evaluated the scenario of neutralizing monoclonal
antibodies (nAbs). Using foresight tools, 227 nAbs were found and an extensive literature review of 16 nAbs in the late clinical development was performed. The results show that pharmaceutical industry continues to invest in new nAbs. These
drugs will probably continue to be relevant in patients that do not show an adequate immunological response to vaccination.
University of Oregon
Large Scale Expression of Human Proteome Antigen Libraries in E. coli
Currently antibody generation is carried out against a single antigen target. We aim to enable antigen multiplexing using scalable technologies for gene
synthesis, library-on-library screening, antibody generation, and antigen-antibody interaction assays using a heterologous expression system to create an antibody production system against all antigen targets in the human proteome. This project
aspect aims to measure the toxicity of over 13,300 full-length human proteins expressed in E. coli.